Sixth joint meeting of J-Cap and CaPSURE-A multinational perspective on prostate cancer management and patient outcomes

Japanese Journal of Clinical Oncology

Volumn 43, Issue 7, 2013, Pages 756-766

  Akaza, Hideyuki ^a   Hinotsu, Shiro ^b   Cooperberg, Matthew R ^c   Chung, Byung Ha ^d   Lee, Ji Youl ^e   Umbas, Rainy ^f   Tsukamoto, Taiji ^g   Namiki, Mikio ^h   Carroll, Peter ⁱ  

^a UNIVERSITY OF TOKYO   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Yonsei University College of Medicine   (South Korea)

^e The Catholic University of Korea   (South Korea)

^f CIPTO MANGUNKUSUMO HOSPITAL   (Indonesia)

^g SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Active surveillance; Androgen deprivation therapy; Chemoprevention; Overall survival; Prostate cancer; Risk stratification

Indexed keywords

ISOFLAVONE DERIVATIVE;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER INCIDENCE; CANCER PATIENT; CHEMOPROPHYLAXIS; DATA BASE; HORMONAL THERAPY; HUMAN; PROSTATE CANCER; PROSTATECTOMY; SOYBEAN;

ACTIVE SURVEILLANCE; ANDROGEN DEPRIVATION THERAPY; CHEMOPREVENTION; OVERALL SURVIVAL; PROSTATE CANCER; RISK STRATIFICATION;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CHEMOPREVENTION; DISEASE MANAGEMENT; DISEASE-FREE SURVIVAL; EVIDENCE-BASED MEDICINE; GONADOTROPIN-RELEASING HORMONE; HUMANS; INDONESIA; INTERNATIONALITY; JAPAN; KOREA; MALE; POPULATION SURVEILLANCE; PRIMARY PREVENTION; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; UNITED STATES; WATCHFUL WAITING;

EID: 84880141128     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyt071     Document Type: Article

References (44)

1. Ministry for Heath, Welfare and Family Affairs. 2009.
2. National Statistics Office. 2009.
3. Annual report of cancer incidence (2009) and survival (1999-2009) in Korea 2012. National Cancer Information Center, 2012.
4. Cooperberg MR, Hilton JF, Carroll PR. The CAPRA-S score: a straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer 2011;117:5039-46.
5. Globocan 2008. International Agency for Research on Cancer. 2008.
6. Indonesian Urological Association: Guideline on Management of Prostate Cancer. 2011.
7. Umbas R, Mochtar CA, Hamid R. Radical therapy on prostate cancer patient: long-term therapy and survival prediction. Indonesian J Cancer 2010;4:55-60.
8. Wempy S, Chaidir A, Rachmat B, Umbas R. Treatment outcomes of organ-confined prostate cancer in elderly patients: comparison between radiation, hormonal and combination therapy. Int J Urol 2012;19:S283.
9. Utomo NB, Mochtar CA, Umbas R. Primary hormonal treatment in localized and locally advanced prostate cancer: effectiveness and survival predictive factors. Acta Medica Indonesiana 2012;44:10-5.
10. Cooperberg MR, Hinotsu S, Namiki M, et al. Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. J Clin Oncol 2009;27:4306-13.
11. Kitagawa Y, Hinotsu S, Shigehara K, et al. Japan Cancer of the Prostate Risk Assessment for combined androgen blockade including bicalutamide: clinical application and validation. Int J Urol 2012 [epub ahead of print].
12. Maeda O. [Treatment strategy of localized prostate cancer]. Gan to kagaku ryoho Cancer chemotherapy 2003;30:26-31.
13. Fukagai T, Namiki TS, Carlile RG, Yoshida H, Namiki M. Comparison of the clinical outcome after hormonal therapy for prostate cancer between Japanese and Caucasian men. BJU Int 2006;97:1190-3.
14. Akaza H, Homma Y, Usami M, et al. Efficacy of primary hormone therapy for localized or locally advanced prostate cancer: results of a 10-year follow-up. BJU Int 2006;98:573-9.
15. Conti PD, Atallah AN, Arruda H, Soares BG, El Dib RP, Wilt TJ. Intermittent versus continuous androgen suppression for prostatic cancer. Cochrane Database Syst Rev 2007;CD005009.
16. Calais da Silva FE, Bono AV, Whelan P, et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol 2009;55:1269-77.
17. Langenhuijsen JF, Badhauser D, Schaaf B, Kiemeney LA, Witjes JA, Mulders PF. Continuous versus intermittent androgen deprivation therapy for metastatic prostate cancer. Urol Oncol 2011.
18. Salonen AJ, Taari K, Ala-Opas M, Viitanen J, Lundstedt S, Tammela TL. The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer. J Urol 2012;187:2074-81.
19. Hussain M, Tangen CM, Higano CS, et al. Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): Results of S9346 (INT-0162), an international phase III trial. Am Soc Clin Oncol 2012.
20. Hussain M, Tangen CM, Higano C, et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 2006;24:3984-90.
21. Hussain M, Goldman B, Tangen C, et al. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol 2009;27:2450-6.
22. Clinical Practice Guidelines in Oncology-Prostate Cancer. National Comprehensive Cancer Network, 2011.
23. AUA guideline for the management of clinically localized prostate cancer: 2007 update. American Urological Association, 2007.
24. Clinical Practice Guidelines in Oncology: Asia Consensus Statement-Prostate Cancer. National Comprehensive Cancer Network, 2011.
25. Cooperberg MR, Vickers AJ, Broering JM, Carroll PR. Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer 2010;116:5226-34.
26. Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 2010;28:1117-23.
27. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist. J Natl Cancer Inst 2006;98:839-45.
28. Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association. Int J Urol 2005;12:46-61.
29. Fujimoto H, Nakanishi H, Miki T, et al. Oncological outcomes of the prostate cancer patients registered in 2004: report from the Cancer Registration Committee of the JUA. Int J Urol 2011;18:876-81.
30. Akaza H. Carroll P, Cooperberg MR, Hinotsu S. Fifth Joint Meeting of J-CaP and CaPSURE: advancing the global understanding of prostate cancer and its management. Jpn J Clin Oncol 2012;42:226-36.
31. Yan L, Spitznagel EL. Meta-analysis of soy food and risk of prostate cancer in men. Int J Cancer J Int du cancer 2005;117:667-9.
32. Lund TD, Munson DJ, Haldy ME, Setchell KD, Lephart ED, Handa RJ. Equol is a novel anti-androgen that inhibits prostate growth and hormone feedback. Biol Reprod 2004;70:1188-95.
33. Akaza H, Miyanaga N, Takashima N, et al. Comparisons of percent equol producers between prostate cancer patients and controls: case-controlled studies of isoflavones in Japanese, Korean and American residents. Jpn J Clin Oncol 2004;34:86-9.
34. Fujimoto K, Tanaka M, Hirao Y, et al. Age-stratified serum levels of isoflavones and proportion of equol producers in Japanese and Korean healthy men. Prostate cancer Prostatic Dis 2008;11:252-7.
35. Miyanaga N, Akaza H, Hinotsu S, et al. Prostate cancer chemoprevention study: an investigative randomized control study using purified isoflavones in men with rising prostate-specific antigen. Cancer Sci 2012;103:125-30.
36. Crawford ED, Andriole GL, Marberger M, Rittmaster RS. Reduction in the risk of prostate cancer: future directions after the Prostate Cancer Prevention Trial. Urology 2010;75:502-9.
37. Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CAs 2012;62:220-41.
38. Etzioni R, Gulati R, Tsodikov A, et al. The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. Cancer 2012.
39. Bechis SK, Carroll PR, Cooperberg MR. Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol 2011;29:235-41.
40. Wilt TJ, Brawer MK, Jones KM, et a.l. Radical prostatectomy versus observation for localized prostate cancer. N England J 2012;367:203-13.
41. Dall'era MA, Albertsen PC, Bangma C, et al. Active surveillance for Prostate Cancer: A Systematic Review of the Literature. Eur Urol 2012;62:976-83.
42. Newcomb LF, Brooks JD, Carroll PR, et al. Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepository. Urology 2010;75:407-13.
43. Cuzick J, Swanson GP, Fisher G, et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol 2011;12:245-55.
44. Cooperberg MR, Simko JP, Cowan JE, et al. Validation of a panel of cell-cycle progression genes for improved risk stratification in a contemporary radical prostatectomy cohort. J Clin Oncol 2013;31: 1428-34.